Objective To measure and assess the significance of myocardial extracellular volume (ECV), determined non-invasively by equilibrium contrast cardiovascular magnetic resonance, as a clinical biomarker in health and a number of cardiac diseases of varying pathophysiology.
Design Prospective study.
Setting Tertiary referral cardiology centre in London, UK.
Patients 192 patients were mainly recruited from specialist clinics. We studied patients with Anderson–Fabry disease (AFD, n=17), dilated cardiomyopathy (DCM, n=31), hypertrophic cardiomyopathy (HCM, n=31), severe aortic stenosis (AS, n=66), cardiac AL amyloidosis (n=27) and myocardial infarction (MI, n=20). The results were compared with those for 81 normal subjects.
Results In normal subjects, ECV (mean (95% CI), measured in the septum) was slightly higher in women than men (0.273 (0.264 to 0.282 vs 0.233 (0.225 to 0.244), p<0.001), with no change with age. In disease, the ECV of AFD was the same as in normal subjects but higher in all other diseases (p<0.001). Mean ECV was the same in DCM, HCM and AS (0.280, 0.291, 0.276 respectively), but higher in cardiac AL amyloidosis and higher again in MI (0.466 and 0.585 respectively, each p<0.001). Where ECV was elevated, correlations were found with indexed left ventricular mass, end systolic volume, ejection fraction and left atrial area in apparent disease-specific patterns.
Conclusions Myocardial ECV, assessed non-invasively in the septum with equilibrium contrast cardiovascular magnetic resonance, shows gender differences in normal individuals and disease-specific variability. Therefore, ECV shows early potential to be a useful biomarker in health and disease.
Statistics from Altmetric.com
- extracellular volume
- cardiac function
- imaging and diagnostics
- myocardial disease
- myocardial fibrosis
- myocardial ischaemia and infarction (IHD)
- sudden adult death syndrome
- cardiomyopathy hypertrophic
- arrhythmic right ventricular dysplasia
- congenital heart disease
- thoracic imaging
- cardiac anatomy
- paediatric cardiac function
- myocardial infarction
- ischaemia reperfusion
- myocardial protection
- metabolic medicine
- diabetic heart disease
- cardiomyopathy apical
- cardiomyopathy restrictive
- hypertrophic cardiomyopathy
- cardiac imaging
Funding (1) British Heart Foundation; (2) Genzyme (for the Anderson–Fabry arm of the study).
Competing interests RHL: received honoraria, consulting fees or grant funding from Genzyme, Shire and Amicus. DAH: travel, research support and honoraria for speaking and being on advisory boards from Shire, Genzyme and Glaxo SmithKline/Amicus. EM: unrestricted educational grants, travel expenses and honoraria from Shire and Genzyme. PME: consulting fees for Shire and Genzyme and speaker fees for Shire.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.